A review of pharmacogenetic studies in the Bangladeshi population.

Md Shaki Mostaid, Md Abdul Aziz, Jeba Atkia Maisha, Mohammad Safiqul Islam, Abdullah Al Maruf

Journal: Drug metabolism and personalized therapy 2023;38(2):123-131

PMID: 36854045

Abstract

Pharmacogenetics (PGx)-guided prescribing is an evidence-based precision medicine strategy. Although the past two decades have reported significant advancements in both the quality and quantity of PGx research studies, they are seldom done in developing countries like Bangladesh. This review identified and summarized PGx studies conducted in the Bangladeshi population by searching PubMed and Google Scholar. Additionally, a quality evaluation of the identified studies was also carried out. Eleven PGx studies were identified that looked at the effects of genetic variants on blood thinners (, , and ), cancer drugs (, , , , , , , , , and ), statins (, , and ), and prednisolone (, , and ) in the Bangladeshi population. Most studies were of low to moderate quality. Although the identified studies demonstrated the potential for PGx testing, the limited PGx literature in the Bangladeshi population poses a significant challenge in the widespread implementation of PGx testing in Bangladesh.

© 2023 Walter de Gruyter GmbH, Berlin/Boston.

Address: Department of Pharmaceutical Sciences, North South University, Dhaka, Bangladesh.; Laboratory of Pharmacogenomics and Molecular Biology, Department of Pharmacy, Noakhali Science and Technology University, Noakhali, Bangladesh.; Department of Mathematics and Natural Sciences, Brac University, Dhaka, Bangladesh.; The Mathison Centre for Mental Health Research & Education, Cumming School of Medicine, University of Calgary, Calgary, Canada.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.